DalsnaFinance Account

Revvity $RVTY

Health Care · Health Care Equipment · NYSE/NASDAQ

S&P 500 Russell 1000 Massachusetts

Create a scorecard

$152.12

-2.96 (-1.91%)

As of Oct 15, 2026, 12:29 AM EDT

Price history

Loading chart…

Revvity (RVTY) is trading down at $152.12 (-1.91%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Revvity revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

Revvity annual financial statements
	FY2016Jan 2017	FY2017Dec 2017	FY2018Dec 2018	FY2019Dec 2019	FY2020Jan 2021	FY2021Jan 2022	FY2022Jan 2023	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$2.12B	$2.26B	$2.78B	$2.88B	$3.78B	$3.83B	$3.31B	$2.75B	$2.76B	$2.86B
Growth (year over year)	+0.5%	+6.7%	+23.1%	+3.8%	+31.2%	+1.2%	−13.5%	−16.9%	+0.2%	+3.7%
Gross profit	$1.01B	$1.07B	$1.34B	$1.40B	$2.11B	$2.43B	$1.99B	—	—	—
Gross margin	47.9%	47.6%	48.3%	48.4%	55.8%	63.6%	60.1%	—	—	—
Operating income	$294.6M	$295.6M	$323.9M	$362.0M	$867.3M	$1.26B	$742.7M	$300.6M	$346.7M	$356.6M
Operating margin	13.9%	13.1%	11.7%	12.6%	22.9%	32.9%	22.4%	10.9%	12.6%	12.5%
Net income	$234.3M	$292.6M	$237.9M	$227.6M	$727.9M	$943.2M	$569.2M	$693.1M	$270.4M	$241.2M
Net margin	11.1%	13.0%	8.6%	7.9%	19.2%	24.6%	17.2%	25.2%	9.8%	8.4%
EPS (diluted)	$2.12	$2.64	$2.13	$2.04	$6.49	$8.08	$4.50	$5.55	$2.20	$2.07
Balance sheet
Cash and equivalents	$359.3M	$202.1M	$163.1M	$191.9M	$387.1M	$603.3M	$454.4M	$913.2M	$1.16B	$919.9M
Total assets	$4.28B	$6.09B	$5.98B	$6.54B	$7.96B	$15.0B	$14.1B	$13.6B	$12.4B	$12.2B
Total liabilities	$2.12B	$3.59B	$3.39B	$3.72B	$4.22B	$7.86B	$6.75B	$5.69B	$4.73B	$4.92B
Long-term debt	$1.05B	$1.79B	$1.88B	$2.06B	$1.61B	$4.98B	$3.92B	$3.18B	$3.15B	$2.63B
Shareholders' equity	$2.15B	$2.50B	$2.58B	$2.81B	$3.74B	$7.14B	$7.38B	$7.87B	$7.67B	$7.25B
Cash flow
Operating cash flow	$350.6M	$288.5M	$311.0M	$363.5M	$892.2M	$1.41B	$679.8M	$91.3M	$628.3M	$582.9M
Capital expenditure	$31.7M	$39.1M	$93.3M	$76.3M	$63.6M	$86.0M	$85.6M	$81.4M	$86.6M	$73.5M
Free cash flow	$318.9M	$249.4M	$217.8M	$287.1M	$828.5M	$1.32B	$594.2M	$9.90M	$541.7M	$509.4M
Dividends paid	$30.8M	$30.8M	$31.0M	$31.1M	$31.2M	$32.4M	$35.3M	$35.0M	$34.5M	$32.8M
Share buybacks	$151.8M	$3.83M	$57.4M	$6.31M	$6.94M	$73.1M	$80.6M	$388.9M	$369.6M	$820.8M

RevenueNet incomeNet margin (right axis, %)

Revvity quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Apr 2026	Q2 FY26Jul 2026
Income statement
Revenue	$684.0M	$729.4M	$664.8M	$720.3M	$698.9M	$772.1M	$711.1M	$729.7M
Growth (year over year)	+2.0%	+4.8%	+2.3%	+4.1%	+2.2%	+5.9%	+7.0%	+1.3%
Gross profit	$384.8M	—	$375.5M	$392.6M	$374.6M	—	$387.7M	$416.9M
Gross margin	56.3%	—	56.5%	54.5%	53.6%	—	54.5%	57.1%
Operating income	$98.2M	$118.8M	$72.2M	$90.8M	$81.9M	$111.7M	$75.9M	$89.3M
Operating margin	14.3%	16.3%	10.9%	12.6%	11.7%	14.5%	10.7%	12.2%
Net income	$94.4M	$94.6M	$42.2M	$53.9M	$46.7M	$98.4M	$40.7M	$51.8M
Net margin	13.8%	13.0%	6.4%	7.5%	6.7%	12.7%	5.7%	7.1%
EPS (diluted)	$0.77	$0.77	$0.35	$0.46	$0.40	$0.86	$0.36	$0.47
Balance sheet
Cash and equivalents	$1.23B	$1.16B	$1.14B	$991.8M	$931.4M	$919.9M	$860.3M	$1.02B
Total assets	$12.8B	$12.4B	$12.4B	$12.4B	$12.1B	$12.2B	$12.0B	$12.0B
Total liabilities	$4.85B	$4.73B	$4.72B	$4.81B	$4.76B	$4.92B	$4.81B	$4.82B
Long-term debt	$3.19B	$3.15B	$3.17B	$3.21B	$2.63B	$2.63B	$2.63B	$2.63B
Shareholders' equity	$7.92B	$7.67B	$7.64B	$7.56B	$7.38B	$7.25B	$7.18B	$7.23B
Cash flow
Operating cash flow	$147.9M	$174.2M	$128.2M	$134.3M	$138.5M	$182.0M	$115.2M	$191.9M
Capital expenditure	$22.3M	$24.5M	$16.0M	$18.9M	$18.5M	$20.2M	$19.8M	$11.1M
Free cash flow	$125.6M	$149.8M	$112.2M	$115.5M	$120.0M	$161.8M	$95.5M	$180.9M
Dividends paid	$8.63M	$8.54M	$8.43M	$8.28M	$8.13M	$7.96M	$7.84M	$7.81M
Share buybacks	$154.1M	$185.2M	$153.6M	$293.9M	$205.0M	$168.3M	$86.5M	$16.0M

From Revvity's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Revvity

Revvity, Inc. is a multinational company headquartered in Waltham, Massachusetts, USA, in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.

Source: Wikipedia — Revvity